Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report
Abstract Background The discovery of epidermal growth factor receptor oncogenic driver mutations has changed the therapeutic landscape of advanced non-small cell lung cancer in the past decade. Since the introduction of next-generation sequencing, uncommon epidermal growth factor receptor mutations...
Saved in:
Main Authors: | Lander Van Acker, Dieter Stevens, Karim Vermaelen, Veerle Surmont |
---|---|
Format: | article |
Language: | EN |
Published: |
BMC
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/52eb1e13ea884b6cbb63be2a7bb85b52 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of afatinib in the treatment of advanced lung squamous cell carcinoma
by: Vavalà T
Published: (2017) -
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
by: Yurong Wang, et al.
Published: (2021) -
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
by: Akiko Takahashi, et al.
Published: (2018) -
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
by: Zhang SS, et al.
Published: (2021) -
Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
by: Ziyu Wang, et al.
Published: (2021)